

Trial to optimize immunotherapy in early TNBC

Prof Michail Ignatiadis MD, PhD
Institut Bordet, Université Libre de Bruxelles,
Chair, Breast Cancer Group EORTC

Question

Can we identify those patients with high risk
TNBC that DO NOT need 1 year of
pembrolizumab in high risk early TNBC?

Study design

Standard neoadjuvant
chemotherapy +
pembrolizumab for
high-risk TNBC

S
Y
R
G
E
R
Y

R

No adjuvant pembrolizumab

Adjuvant pembrolizumab (27 weeks)

Stratification for pathological complete response at surgery

Expected impact

- Optimize adjuvant treatment duration in high-risk early TNBC
- Spare young women with TNBC from toxicity related to 1 year of pembrolizumab
- Spare society and EU states from a costly treatment